The Effect of Pantoprazole on Bone Turnover in Ovariectomized ICR Mice.
- Author:
Eun Hye LIM
1
;
Key Hyeon KIM
;
Beom Jae LEE
;
Moon Kyung JOO
;
Jin Sung KOH
;
Joon Young LEE
;
Sang Ah LIM
;
Ji Hoon KIM
;
Jong Eun YEON
;
Jong Jae PARK
;
Jae Seon KIM
;
Kwan Soo BYUN
;
Young Tae BAK
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. gi7pjj@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Pantoprazole;
Osteoporosis;
Bone turnover
- MeSH:
2-Pyridinylmethylsulfinylbenzimidazoles;
Alkaline Phosphatase;
Animals;
Bone Density;
Calcium;
Cytokines;
Enzyme-Linked Immunosorbent Assay;
Female;
Humans;
Injections, Intraperitoneal;
Interleukin-6;
Interleukins;
Mice;
Mice, Inbred ICR;
Osteocalcin;
Osteoclasts;
Osteogenesis;
Osteoporosis;
Phosphorus;
Proton Pump Inhibitors;
Proton Pumps;
RNA, Messenger;
Sample Size;
Tibia;
Tumor Necrosis Factor-alpha
- From:Korean Journal of Medicine
2011;80(1):56-62
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Long-term exposure to proton pump inhibitors is associated with osteoporosis-related fractures; however, the mechanism is unknown. The purpose of this study was to evaluate the effect of pantoprazole on osteoporosis and bone turnover in ovariectomized ICR mice fed a calcium-free diet. METHODS: Ovariectomized female ICR mice were divided into a pantoprazole group (n=10) and a control group (n=10). The mice in the pantoprazole group were given an intraperitoneal injection of pantoprazole at 20 mg/kg twice daily. After 4 weeks, the mice were humanely euthanized, and bone mineral density (BMD) and dry tibia weight were measured. Serum osteocalcin and CTX-1 levels were measured by enzyme-linked immunosorbent assay. The mRNA expression levels of cytokines that stimulate osteoclast differentiation were determined using RT-PCR. Serum calcium, phosphorus, and alkaline phosphatase (ALP) levels were also analyzed. RESULTS: Serum osteocalcin concentration was significantly lower in the pantoprazole group compared with the control group (p=0.023). There was no difference in BMD, dry tibia weight, or serum ALP, calcium, phosphorus, or CTX-1 between the two groups. The expression of interleukin (IL)-1beta was lower in the pantoprazole group compared with the control group, but not significantly lower (p=0.058). The levels of tumor necrosis factor-alpha and IL-6 did not differ between the two groups. CONCLUSIONS: Pantoprazole, a proton pump inhibitor, decreased serum osteocalcin and suppressed IL-1beta expression, suggesting that pantoprazole affects bone formation and resorption in ovariectomized ICR mice. Further studies using larger sample sizes are needed.
